Company

Biotest - Innovation in haematology,
clinical immunology and intensive care medicine

Further information

Research and development

Specialist for Immune Sciences

Further information

Investor Relations

Create value for our shareholders

Further information

Patients

Biotest products save lives and offer new perspectives to chronically ill patients

Further information

Careers

Passionate to help us save lives?

Further information

Our product range

Haematology Clinical immunology Intensive care medicine

Haematology

For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.

Further information

Clinical immunology

Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).

Further information

Intensive care medicine

Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.

Further information

Our development pipeline

	Phase 1	Phase 2	Phase 3	Approval	Launch
	IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
	IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
	Fibrinogen (BT524) - Congenital fibrinogen deficiency
	Fibrinogen (BT524) - Acquired fibrinogen deficiency
	Trimodulin (BT588) - Severe community acquired pneumonia

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Press releases

Biotest increases sales by 1.8% to EUR 294.9 million

14.11.2019,

14.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ... [More]

Biotest shows excellent efficacy and tolerability of Ha...

29.10.2019,

Biotest shows excellent efficacy and tolerability of Haemoctin(R) SDH in long-term study of patients with haemophilia A - Clinical data of the worldwide longest surveillance study on198 patients repre ... [More]

Biotest Achieves Important Clinical Milestone for IgG N...

05.09.2019,

Biotest Achieves Important Clinical Milestone for IgG Next Generation- Phase III study in Primary Immune Thrombocytopenia (ITP) completed, data evaluation in progress, promising results - The study is ... [More]

Biotest increases adjusted EBIT by 12% to EUR 29.9 mill...

14.08.2019,

Biotest increases adjusted EBIT by 12% to EUR 29.9 million- Earnings after taxes reaches EUR 2.0 million- Expansion project Biotest Next Level proceeding according to plan- Long-term financing of the ... [More]

Annual general meeting approves payout of dividend

07.05.2019,

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 07 May 2019. At the annual general meeting (AGM) held on 07 M ... [More]

Biotest reaches revenues of EUR 77.5 million in the fir...

07.05.2019,

Biotest reaches revenues of EUR 77.5 million in the first quarter 2019 - Guidance confirmed- Earnings after taxes in the first quarter totalled to EUR -1.2 million Dreieich, 7 May 2019. In the first q ... [More]

Biotest AG opens ninth plasma collection centre in Hung...

09.04.2019,

Biotest AG opens ninth plasma collection centre in Hungary- 21 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 9 April 2019. Biotest received an operating permit for its ... [More]

Biotest increases operating result by EUR 20 million in...

28.03.2019,

Biotest increases operating result by EUR 20 million in 2018- EBIT rises to EUR 10.6 million- Sales grow by 5.9% to EUR 400.3 million- Biotest meets sales and EBIT forecast Dreieich, 28 March 2019. In ... [More]

Biotest receives approval for double concentrated Haemo...

12.03.2019,

Biotest receives approval for double concentrated Haemoctin(R) SDH for improved haemophilia A treatment in Europe- Increased patient convenience: Volume reduction of the factor VIII concentrate Haemoc ... [More]

Biotest increases operating result by EUR 20 million in...

07.03.2019,

Biotest increases operating result by EUR 20 million in 2018- EBIT rises to EUR 10.6 million- Sales grow by 5.9% to EUR 400.3 million- Biotest meets sales and EBIT forecast Dreieich, 07 March 2019. Ac ... [More]

Dr Michael Ramroth to become new CEO of Biotest AG

07.03.2019,

Announcement according to Article 17 European Market Abuse Regulation (MAR)Dr Michael Ramroth to become new CEO of Biotest AGDreieich, 7 March 2019. The Supervisory Board of Biotest AG, in its meeting ... [More]

Biotest receives Intratect(R) approval for additional i...

24.01.2019,

Biotest receives Intratect(R) approval for additional indications in 22 European countries- Additional fields of use in neurology (CIDP, MMN) and secondary immunodeficiencies (SID) - 40% of the global ... [More]

Correction of a release from 11/12/2018 according to Ar...

12.12.2018,

Notification of Major Holdings1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): 529900JVX7RPXBLYUD892. Reason fo ... [More]

Release according to Article 40, Section 1 of the WpHG ...

11.12.2018,

Notification of Major Holdings1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): 529900JVX7RPXBLYUD892. Reason fo ... [More]

Biotest AG takes next step in developing a new haemophi...

04.12.2018,

Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs - Biotest exercises its option and receives exclusive rights for haemophilia on the use of Affibody's Alb ... [More]

Hepatect(R) CP and Zutectra(R) show marked efficacy in ...

20.11.2018,

Hepatect(R) CP and Zutectra(R) show marked efficacy in the prevention of HBV reinfection after liver transplantation in long-term study- 371 liver transplanted patients observed over almost seven year ... [More]

Biotest AG acquires ninth plasma collection center in G...

15.11.2018,

Biotest AG acquires ninth plasma collection center in Germany- 100% subsidiary Plasma Service Europe takes over plasma centre in Hanover- In the future, 20 plasma collection centres in Europe to ensur ... [More]

Biotest increases sales in the first nine months of 201...

14.11.2018,

Biotest increases sales in the first nine months of 2018 to EUR 289.6 million- EBIT of EUR 5.1 million despite expenses of EUR 37.8 million for the Biotest Next Level project- Successful qualification ... [More]

Preliminary announcement of the publication of quarterl...

12.11.2018,

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2019: Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / ... [More]

Preliminary announcement of the publication of financia...

12.11.2018,

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2018: Report: Annual financial report Date of disclosure / German: March 28, 2019 Date of d ... [More]

Careers

Careers

Passionate to help us save lives?

Further information

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Further information